Inhibition of the BMP pathway suppresses tumor growth via downregulation of EGFR in MEK/ERK-dependent colorectal cancer

The bone morphogenetic protein (BMP) pathway promotes differentiation and induces apoptosis in normal colorectal epithelial cells. However, the effect of the BMP pathway in colorectal cancer (CRC) is controversial; it can either be tumor promoting or tumor suppressing, depending on the study. In this study, we found that CRC cells reside in a BMP-rich environment based on RNA-sequencing database analysis. Suppression of BMP using a specific BMP inhibitor, LDN193189, suppresses the growth of organoids in some CRC cases. CRC organoids treated with LDN193189 exhibited a decrease in epidermal growth factor receptor, which was, at least in part, mediated by protein degradation induced by leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1). Among CRC organoid panels from 18 different patients, suppression of organoid growth by BMP inhibition correlated with the induction of LRIG1 gene expression. Notably, knockdown of LRIG1 in organoids diminished the growth-suppressive effect of LDN193189. Furthermore, simultaneous treatment with LDN192189 and trametinib, an FDA-approved MEK inhibitor, resulted in a combination effect in both in vivo and in vitro xenograft tumor treatment in CRC organoids, which are susceptible to growth suppression by LDN193189. Taken together, the simultaneous inhibition of BMP and MEK can be a novel treatment option in CRC cases, and evaluating in vitro growth suppression and LRIG1 induction by BMP inhibition using patient-derived organoids could offer functional biomarkers for predicting potential responders.

[1]  K. Miyazono,et al.  Bone Morphogenetic Protein Signaling in Cancer; Some Topics in the Recent 10 Years , 2022, Frontiers in Cell and Developmental Biology.

[2]  D. Threadgill,et al.  Cross‐talk between EGFR and BMP signals regulates chondrocyte maturation during endochondral ossification , 2021, Developmental dynamics : an official publication of the American Association of Anatomists.

[3]  L. Siu,et al.  Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. , 2021, Clinical colorectal cancer.

[4]  L. V. Valkenburg-van Iersel,et al.  Combined targeted therapy for BRAF mutant metastatic colorectal cancer: are we there yet? , 2021, Digestive Medicine Research.

[5]  S. Angaji,et al.  LRIG1 expression and colorectal cancer prognosis , 2020, BMC Medical Genomics.

[6]  W. Jiang,et al.  Noggin is associated with a poor prognosis of gastric cancer by promoting the proliferation of gastric cancer cells via the upregulation of EGFR. , 2020, International Journal of Oncology.

[7]  Y. Cho,et al.  Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer , 2020, Nature Genetics.

[8]  Z. Wainberg,et al.  Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors , 2019, Front. Oncol..

[9]  M. Inoue,et al.  Application of Cancer Organoid Model for Drug Screening and Personalized Therapy , 2019, Cells.

[10]  Yan-ting Zhu,et al.  Clinicopathological and prognostic significance of leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) in malignant tumors: A meta-analysis , 2018, Journal of Cancer.

[11]  J. Neefjes,et al.  The EGFR odyssey – from activation to destruction in space and time , 2017, Journal of Cell Science.

[12]  M. Ohue,et al.  In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer , 2017, PloS one.

[13]  Bing Zhao,et al.  BMP restricts stemness of intestinal Lgr5+ stem cells by directly suppressing their signature genes , 2017, Nature Communications.

[14]  Jingwen Ye,et al.  Lrig1 is a positive prognostic marker in hepatocellular carcinoma , 2016, OncoTargets and therapy.

[15]  C. Hong,et al.  Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition. , 2016, Biochemical Society transactions.

[16]  Zibo Zhao,et al.  Expression of LRIG1 is Associated With Good Prognosis for Human Non-small Cell Lung Cancer , 2015, Medicine.

[17]  K. Edlund,et al.  LRIG1 is a prognostic biomarker in non-small cell lung cancer , 2015, Acta oncologica.

[18]  R. Coffey,et al.  LRIG1 Regulates Ontogeny of Smooth Muscle-Derived Subsets of Interstitial Cells of Cajal in Mice. , 2015, Gastroenterology.

[19]  G. R. van den Brink,et al.  A protocol for lentiviral transduction and downstream analysis of intestinal organoids. , 2015, Journal of visualized experiments : JoVE.

[20]  R. Tollenaar,et al.  The BMP pathway either enhances or inhibits the Wnt pathway depending on the SMAD4 and p53 status in CRC , 2014, British Journal of Cancer.

[21]  B. Barres,et al.  BMP Signaling in Astrocytes Downregulates EGFR to Modulate Survival and Maturation , 2014, PloS one.

[22]  C. Futter,et al.  EGF receptor trafficking: consequences for signaling and cancer , 2014, Trends in cell biology.

[23]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[24]  R. Coffey,et al.  LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor , 2013, British Journal of Cancer.

[25]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[26]  P. Ordóñez-Morán,et al.  Lrig1: a new master regulator of epithelial stem cells , 2012, The EMBO journal.

[27]  Bruce J. Aronow,et al.  The Pan-ErbB Negative Regulator Lrig1 Is an Intestinal Stem Cell Marker that Functions as a Tumor Suppressor , 2012, Cell.

[28]  O. Griffith,et al.  Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer , 2011, Molecular Cancer Research.

[29]  H. Iishi,et al.  Retaining cell–cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer , 2011, Proceedings of the National Academy of Sciences.

[30]  D. Jonker,et al.  The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. , 2011, Discovery medicine.

[31]  L. Ricci-Vitiani,et al.  Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. , 2011, Gastroenterology.

[32]  A. Ruiz i Altaba,et al.  BMP signaling promotes the growth of primary human colon carcinomas in vivo. , 2010, Journal of molecular cell biology.

[33]  E. Maspero,et al.  A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation , 2010, The Journal of cell biology.

[34]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[35]  Angelique M. Nelson,et al.  Self-renewal of human embryonic stem cells requires insulin-like growth factor-1 receptor and ERBB2 receptor signaling. , 2007, Blood.

[36]  Suet Yi Leung,et al.  Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors , 2007, Proceedings of the National Academy of Sciences.

[37]  J. Carethers,et al.  Bone morphogenetic protein signaling and growth suppression in colon cancer. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[38]  Xiuli Wu,et al.  The Leucine-rich Repeat Protein LRIG1 Is a Negative Regulator of ErbB Family Receptor Tyrosine Kinases* , 2004, Journal of Biological Chemistry.

[39]  Ossama Tawfik,et al.  BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt–β-catenin signaling , 2004, Nature Genetics.

[40]  I. Amit,et al.  LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation , 2004, The EMBO journal.